2026 Q1 Formulary Policy Updates
Catch up on Q1 2026 formulary policy updates, including important changes that may affect drug coverage, prescribing practices, and member access to medications.
Published January 2026
Below is a list of medications recently reviewed by the MVP Pharmacy and Therapeutics Committee. For coverage information regarding these medications, please review the MVP Formularies available at Pharmacy Information for Providers . For more detailed information regarding pharmacy changes, please review Provider FastFax Library or visit all policies MVP Health Care Medical Policy.
A list of formulary changes for Plan Year 2025 is available for review: 2025 Commercial and Marketplace Formulary Changes. Changes will take effect on the member’s pharmacy “Plan Year” start date.
Drugs removed from prior authorization for Commercial, Marketplace, and Self-Funded Formularies
- Grafapex
- Xromi
- Zunveyl
- Inzirqo
- Revuforj
- Rapiblyk
- Tezruly
- Zevtera
- Avmapki
- Emblaveo
- Khindivi
New Drugs excluded for Commercial, Marketplace, and Self-Funded Formularies
- Alhemo
- Raldesy
- Vanrafia
- Qfitlia
- Symbravo
New generics that recently came to market
| Brand name | Generic name |
|---|---|
| Xarelto | Rivaroxaban suspension |
| Eprontia | Topiramate solution |
| Dificid | Fidaxomicin tablet |
| Venofer injection; | Iron Sucrose |
| Arnuity Ellipta | Fluticasone Furoate |
| Saxenda | Liraglutide |
Policy Updates
Review other articles in this issue regarding formulary, pharmacy policy, and medical policy updates.